- Detail & Program Access
- Credit Eligibility
- Funding Support
|Drs Milan Gupta, Narendra Singh
|CLICK HERE TO LISTEN
This program was developed by the Canadian Collaborative Research Network.
Heart failure with preserved EF (HFpEF) carries substantial morbidity and mortality, yet evidence-based treatments to improve outcomes are sorely lacking. Recently, the FDA made the unusual decision to approve sacubitril/valsartan for HFpEF despite a neutral trial with this agent. Similarly, while spironolactone’s major trial in HFpEF was not positive, guidelines have endorsed this therapy based on sub-group analyses. This podcast will explore why these decisions were made and whether these treatments should be considered for HFpEF patients.
- To review current treatment strategies for HFpEF
- To understand how neutral trials may still influence guidelines and practice